We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead (GILD) Shares Slip on Earnings Miss, Revenues Down Over 20%
Read MoreHide Full Article
Gilead Sciences Inc. (GILD - Free Report) just released its latest quarterly financial results, posting earnings of $1.48 and revenues of $5.1 billion.
Currently, GILD is a Zacks Rank #2 (Buy), but that could change based on today’s results. Estimates have increased by five cents for the current year over the last two months, and the Zacks Consensus sits at a $6.43 per share.
Shares of the biotech company have grown only 5.5% in the last year and closed the trading day up a slight 0.46%. The stock is down about 5.4% in after-hours trading shortly after the earnings report was released.
Gilead:
Missed earnings estimates. The company reported earnings of $1.48, lagging behind the Zacks Consensus Estimate of $1.66. Net income was $2 billion.
Missed revenue estimates. The company saw revenues of $5.1 billion, also missing our consensus estimate of $5.42 billion and declining 21.5% year-over-year.
Total product sales were $5 billion for the quarter compared to $6.4 billion for the same period in 2017. Antiviral product sales, which include Gilead’s HIV, chronic hepatitis B (HBV), and chronic hepatitis C (HCV) products, hit $4.4 billion, also down compared to the prior-year quarter. Other product sales came in at $626 million for Q1.
Gilead reiterated its full-year 2018 outlook, and still anticipates net product sales in the range of $20 billion to $21 billion for the year.
Here’s a graph that looks at Gilead’s recent earnings performance:
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Its portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius. Click for details >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead (GILD) Shares Slip on Earnings Miss, Revenues Down Over 20%
Gilead Sciences Inc. (GILD - Free Report) just released its latest quarterly financial results, posting earnings of $1.48 and revenues of $5.1 billion.
Currently, GILD is a Zacks Rank #2 (Buy), but that could change based on today’s results. Estimates have increased by five cents for the current year over the last two months, and the Zacks Consensus sits at a $6.43 per share.
Shares of the biotech company have grown only 5.5% in the last year and closed the trading day up a slight 0.46%. The stock is down about 5.4% in after-hours trading shortly after the earnings report was released.
Gilead:
Missed earnings estimates. The company reported earnings of $1.48, lagging behind the Zacks Consensus Estimate of $1.66. Net income was $2 billion.
Missed revenue estimates. The company saw revenues of $5.1 billion, also missing our consensus estimate of $5.42 billion and declining 21.5% year-over-year.
Total product sales were $5 billion for the quarter compared to $6.4 billion for the same period in 2017. Antiviral product sales, which include Gilead’s HIV, chronic hepatitis B (HBV), and chronic hepatitis C (HCV) products, hit $4.4 billion, also down compared to the prior-year quarter. Other product sales came in at $626 million for Q1.
Gilead reiterated its full-year 2018 outlook, and still anticipates net product sales in the range of $20 billion to $21 billion for the year.
Here’s a graph that looks at Gilead’s recent earnings performance:
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead Sciences, Inc. Price, Consensus and EPS Surprise | Gilead Sciences, Inc. Quote
Gilead is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Its portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius. Click for details >>